Tolerance.ca
Director / Editor: Victor Teboul, Ph.D.
Looking inside ourselves and out at the world
Independent and neutral with regard to all political and religious orientations, Tolerance.ca® aims to promote awareness of the major democratic principles on which tolerance is based.

New Alzheimer's drug slows cognitive decline – and may be available as early as next year

By Bernadette McGuinness, Clinical Professor of Ageing, Queen's University Belfast
Elizabeth Coulthard, Associate Professor in Dementia Neurology, University of Bristol
Share this article
Lecanemab is the first drug to help improve the symptoms of Alzheimer’s by slowing the disease. These are very promising results, although the only data we have at the moment is from the drugmaker’s press release.

Lecanemab is an antibody that finds and removes a protein called amyloid that builds up and forms clumps in the brains of people with Alzheimer’s disease. By targeting amyloid, lecanemab is striking at the heart of the disease…The Conversation


Read complete article

© The Conversation -
Subscribe to Tolerance.ca


Follow us on ...
Facebook Twitter